HomeInsightsStock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Samrat Pharmachem Ltd Stock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Samrat Pharmachem Ltd Stock Comparison

Last Updated on: Jul 02, 2025

Key Highlights

  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 3297 as of 02 Jul 12:33.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 52.5 on March 2025 . This represents a CAGR of -21.62% over 6 yearsThe P/E Ratio of Samrat Pharmachem Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 years.
  • The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.98% over 6 yearsThe Market Cap of Samrat Pharmachem Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 years.
  • The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 1015 crore as compare to the Dec '24 revenue of ₹ 984.49 crore. This represent the growth of 3.1% The revenue of Samrat Pharmachem Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 373.87 crore as compare to the Dec '24 ebitda of ₹ 326.99 crore. This represent the growth of 14.34% The ebitda of Samrat Pharmachem Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 262.87 crore over 8 quarters. This represents a CAGR of 40.98% The net profit of Samrat Pharmachem Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 99.54 % on March 2025 . This represents a CAGR of -26.19% over 6 yearsThe Dividend Payout of Samrat Pharmachem Ltd changed from 1.8 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
  • The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Samrat Pharmachem Ltd

  • Samrat Pharmachem Limited was incorporated on June 16, 1992.
  • The Company's principal activities are manufacturing and selling chemicals. The Company floated a new 100% subsidiary company during the year 2003-04 named as Samrat Remedies Limited to carry on activities of Manufacturing of Pharmaceutical Bulk Drugs & Chemicals.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

27 Jun 2025 11:08

News

GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same per...

Read more

14 May 2025 12:47

News

GlaxoSmithKline Pharmaceuticals AGM scheduled

GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the comp...

Read more

13 May 2025 17:18

News

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

13 May 2025 17:18

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

Samrat Pharmachem Ltd News Hub

News

Samrat Pharmachem to convene board meeting

Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 13 Augus...

Read more

24 Jun 2025 09:54

News

Samrat Pharmachem AGM scheduled

Samrat Pharmachem announced that the 33th Annual General Meeting(AGM) of the company will ...

Read more

07 Jun 2025 17:20

News

Board of Samrat Pharmachem recommends final dividend

Samrat Pharmachem announced that the Board of Directors of the Company at its meeting held...

Read more

31 May 2025 12:04

News

Samrat Pharmachem to table results

Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 30 May 2...

Read more

27 Mar 2025 09:23

News

Samrat Pharmachem to declare Quarterly Result

Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 14 Febru...

Read more

31 Dec 2024 19:58

News

Samrat Pharmachem announces board meeting date

Samrat Pharmachem will hold a meeting of the Board of Directors of the Company on 14 Novem...

Read more

28 Sep 2024 10:13

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Samrat Pharmachem Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Samrat Pharmachem Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 56,774 Cr while Market cap of Samrat Pharmachem Ltd is 109 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd?

As of July 2, 2025, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹3351.4. On the other hand, Samrat Pharmachem Ltd stock price is INR ₹352.8.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Samrat Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions